Browsing by Author "Sridhar, Srikala S."

Sort by: Order: Results:

  • Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice
    Grivas, Petros; Agarwal, Neeraj; Pal, Sumanta; Kalebasty, Arash Rezazadeh; Sridhar, Srikala S.; Smith, Jodi; Devgan, Geeta; Sternberg, Cora N.; Bellmunt Molins, Joaquim, 1959- (Elsevier, 2021)
    Although urothelial carcinoma (UC) is considered a chemotherapy-sensitive tumor, progression-free survival and overall survival (OS) are typically short following standard first-line (1L) platinum-containing chemotherapy ...
  • Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
    Powles, Thomas; Sridhar, Srikala S.; Loriot, Yohann; Bellmunt Molins, Joaquim, 1959-; Mu, Xinmeng Jasmine; Ching, Keith A.; Pu, Jie; Sternberg, Cora N.; Petrylak, Daniel P.; Tambaro, Rosa; Dourthe, Louis M.; Alvarez-Fernandez, Carlos; Aarts, Maureen; Di Pietro, Alessandra; Grivas, Petros; Davis, Craig B. (Nature Research, 2021)
    In a recent phase 3 randomized trial of 700 patients with advanced urothelial cancer (JAVELIN Bladder 100; NCT02603432 ), avelumab/best supportive care (BSC) significantly prolonged overall survival relative to BSC alone ...
  • Efficacy of surgery in the primary tumor site for metastatic urothelial cancer: analysis of an international, multicenter, multidisciplinary database
    Moschini, Marco; Xylinas, Evanguelos; Zamboni, Stefania; Mattei, Agostino; Niegisch, Günter; Yu, Evan Y.; Bamias, Aristotle; Agarwal, Neeraj; Sridhar, Srikala S.; Sternberg, Cora N.; Vaishampayan, Ulka N.; Rosenberg, Jonathan E.; Bellmunt Molins, Joaquim, 1959-; Galsky, Matthew D.; Montorsi, Francesco; Necchi, Andrea; RISC Investigators (Elsevier, 2020)
    Purpose: SUDEP is the first cause of mortality related to epilepsy. However, in Spain there are no published cases or series from Epilepsy Monitoring Units that could expose the characteristics of SUDEP in our population. ...
  • Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial
    Pal, Sumanta; Somford, Diederik M.; Grivas, Petros; Sridhar, Srikala S.; Gupta, Shilpa; Bellmunt Molins, Joaquim, 1959-; Sonpavde, Guru; Fleming, Mark T.; Lerner, Seth Paul; Loriot, Yohann; Hoffman-Censits, Jean; Valderrama, Begoña P.; Andresen, Corina; Schnabel, Marco J.; Cole, Suzanne; Daneshmand, Siamak (Future Medicine, 2022)
    PROOF 302 is an ongoing randomized, double-blind, placebo-controlled, adjuvant phase III trial (NCT04197986) in approximately 218 patients from 120 centers worldwide. Eligibility criteria include post-surgical high-risk ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking